Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
September 13, 2024
Survival impact of [<sup>225</sup>Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastases
Alexandre Lugat, Nicolas Chouin, Florian Chocteau, et al.
Clinical Nuclear Medicine
|
December 14, 2020
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors
Catherine Ansquer, Yann Touchefeu, Alain Faivre-Chauvet, et al.
Annals of Surgical Oncology
|
May 15, 2014
Quality of life is modestly improved in older patients with mild primary hyperparathyroidism postoperatively: results of a prospective multicenter study
Claire Blanchard, Muriel Mathonnet, Frédéric Sebag, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 22, 2017
Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study
Carole Guerin, François Pattou, Laurent Brunaud, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 20, 2007
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy
Aurore Oudoux, Pierre-Yves Salaun, Claire Bournaud, et al.
Cancers
|
January 21, 2023
Prospective Multicentric Assessment of <sup>68</sup>Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET
Alexandre Lugat, Éric Frampas, Yann Touchefeu, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 26, 2024
Dosimetry and pharmacokinetics of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Seval Beykan Schürrle, Uta Eberlein, Catherine Ansquer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 6, 2021
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 9, 2014
¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma
Pierre-Yves Salaun, Loïc Campion, Catherine Ansquer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 30, 2012
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement
Pierre-Yves Salaun, Loïc Campion, Claire Bournaud, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
European Journal of Nuclear Medicine and Molecular Imaging
|
September 13, 2024
Survival impact of [<sup>225</sup>Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastases
Alexandre Lugat, Nicolas Chouin, Florian Chocteau, et al.
Clinical Nuclear Medicine
|
December 14, 2020
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors
Catherine Ansquer, Yann Touchefeu, Alain Faivre-Chauvet, et al.
Annals of Surgical Oncology
|
May 15, 2014
Quality of life is modestly improved in older patients with mild primary hyperparathyroidism postoperatively: results of a prospective multicenter study
Claire Blanchard, Muriel Mathonnet, Frédéric Sebag, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 22, 2017
Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study
Carole Guerin, François Pattou, Laurent Brunaud, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 20, 2007
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy
Aurore Oudoux, Pierre-Yves Salaun, Claire Bournaud, et al.
Cancers
|
January 21, 2023
Prospective Multicentric Assessment of <sup>68</sup>Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET
Alexandre Lugat, Éric Frampas, Yann Touchefeu, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 26, 2024
Dosimetry and pharmacokinetics of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Seval Beykan Schürrle, Uta Eberlein, Catherine Ansquer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 6, 2021
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 9, 2014
¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma
Pierre-Yves Salaun, Loïc Campion, Catherine Ansquer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 30, 2012
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement
Pierre-Yves Salaun, Loïc Campion, Claire Bournaud, et al.
Page
of 5